Liquidia Co. (NASDAQ:LQDA – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 3,170,000 shares, a decrease of 8.4% from the October 15th total of 3,460,000 shares. Based on an average daily volume of 425,800 shares, the short-interest ratio is currently 7.4 days.
Wall Street Analyst Weigh In
LQDA has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $3.00 price objective on shares of Liquidia in a research note on Thursday, November 9th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Liquidia in a report on Friday, August 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Liquidia in a research report on Wednesday, November 8th.
Institutional Investors Weigh In On Liquidia
Liquidia Price Performance
NASDAQ:LQDA traded down $0.05 during trading hours on Friday, hitting $6.26. 241,066 shares of the company traded hands, compared to its average volume of 494,365. Liquidia has a twelve month low of $4.48 and a twelve month high of $9.95. The firm has a 50-day moving average of $6.42 and a 200 day moving average of $7.32.
Liquidia Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
- Five stocks we like better than Liquidia
- Basic Materials Stocks Investing
- 3 large caps with red hot RSIs with upside
- Why Are Stock Sectors Important to Successful Investing?
- Johnson Controls International: Nothing but upside for investors
- Golden Cross Stocks: Pattern, Examples and Charts
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.